Seikagaku International Sales Tumble Amid COVID Surge

Seikagaku's logo

Seikagaku reported FY 1Q20 orthopedic revenue of ¥3,029.1 million (USD $28.2 million), -21.2% vs. 1Q19.

The company suffered negative impact from drug price reductions in Japan as well as spreading COVID infections in its key markets of Japan and the U.S. While Seikagaku increased its market share of viscosupplements in Japan, its overall...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us